Xellia Pharmaceuticals

Xellia Pharmaceuticals is a specialty pharmaceutical company established in 1946, focusing on the development, manufacturing, and commercialization of advanced anti-infective treatments. The firm specializes in addressing serious and life-threatening bacterial and fungal infections through a robust portfolio of critical care therapies. By maintaining a strong commitment to R&D, the company provides essential medical solutions that target complex disease profiles and improve patient safety outcomes globally. Their technical expertise allows them to navigate the rigorous demands of the modern healthcare landscape effectively.

Operating with a workforce of 1,000-5,000 employees, Xellia Pharmaceuticals maintains a significant presence across 5 global locations. The organization leverages its extensive expertise in active pharmaceutical ingredients and finished dosage forms to support healthcare providers worldwide. Meet Xellia Pharmaceuticals's team to understand the leadership and technical talent driving their operational excellence and strategic growth in the pharmaceutical sector. This team is instrumental in managing the complex supply chains required for high-stakes medical manufacturing.

The company’s product scope includes biosimilars, ready-to-use injectable therapies, and key pharmaceutical ingredients. With a legacy spanning over seven decades, Xellia Pharmaceuticals continues to innovate within the anti-infective drug market. Their focus on secure supply chains and high-quality manufacturing standards ensures that critical care facilities receive reliable, effective treatments for patients in need. The firm remains a key player in the healthcare industry, consistently delivering innovative therapeutic options to address evolving medical challenges and ensuring that life-saving medications are accessible to those requiring urgent care.